Aroa BiosurgeryASX:ARX +0.85%62 Current Ratio is 4.77 as of Mar. 2026, which is 34% below its 10-year median of 7.26. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 75.91% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Aroa Biosurgery's current ratio for the quarter that ended in Mar. 2026 was 4.77.
Aroa Biosurgery has a current ratio of 4.77. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Aroa Biosurgery's Current Ratio or its related term are showing as below:
ASX:ARX'
s Current Ratio Range Over the Past 10 Years
Min: 4.5 Med: 7.26 Max: 11.9
Current: 4.77
During the past 7 years, Aroa Biosurgery's highest Current Ratio was 11.90. The lowest was 4.50. And the median was 7.26.
ASX:ARX's Current Ratio is ranked better than 75.91% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 2.48
vs ASX:ARX: 4.77
Aroa Biosurgery (ASX:ARX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Aroa Biosurgery Current Ratio Related Terms
Aroa Biosurgery Current Ratio Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ARX vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Aroa Biosurgery's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Current Ratio distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a Current Ratio of 4.77 as of Mar. 2026. This is 34% below median its historical median of 7.26. Over the past decade, Aroa Biosurgery's Current Ratio has ranged from 4.50 to 11.90. According to the industry distribution chart, Aroa Biosurgery ranks #206 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Aroa Biosurgery's Current Ratio too high?
Aroa Biosurgery's current Current Ratio of 4.77 is 34% below median its 10-year median of 7.26. Over the past 10 years, this metric has ranged from a low of 4.50 to a high of 11.90. The Medical Devices & Instruments industry median Current Ratio is 2.48. Aroa Biosurgery's value of 4.77 is 92.3% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #206 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #206 out of 855 companies for Current Ratio. This places Aroa Biosurgery in the top 24% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.48. Aroa Biosurgery's value of 4.77 is 92.3% above this benchmark. Historically, Aroa Biosurgery's own Current Ratio has ranged from 4.50 to 11.90 over the past decade. While the company's 10-year median is 7.26 vs. the industry median of 2.48, Aroa Biosurgery has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.48, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current Current Ratio of 4.77 is 92.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Current Ratio is 4.77, which is 34% below median its own 10-year median of 7.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current Current Ratio is 4.77, which is 34% below median its 10-year median of 7.26 and 92.3% above the Medical Devices & Instruments industry median of 2.48. Aroa Biosurgery's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Current Ratio is 4.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
Current Ratio: 4.77 (34% below median its 10-year median of 7.26)
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
Industry Position: 92.3% above the Medical Devices & Instruments median (#206 of 855)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
